                                                                   Annex IV 
Conclusions on the request for one-year marketing protection presented by the European 
Medicines Agency 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
Conclusions presented by the European Medicines Agency on: 
ï‚·  one-year marketing protection 
The CHMP reviewed the data submitted by the marketing authorisation holder, taking into account 
the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new 
therapeutic indication brings significant clinical benefit in comparison with existing therapies as 
further explained in the European Public Assessment Report.  
2 
 
 
 
 
  
 
